Circulating tumor cells (CTCs) can be enumerated using CellSearch, but not all breast cancer subtypes, specifically those with epithelial-mesenchymal transition (EMT) characteristics, sufficiently express the enrichment (EpCAM) and selection (CK8/18/19) markers used in this method. While CD146 can detect EpCAM-negative CTCs, we here evaluated the value of various cytokeratins and CD49f to detect CK8/18/19-negative CTCs. The tested cytokeratins provided no substantial benefit, but adding CD49f to CK8/18/19 as a selection marker resulted in improved recovery of normal-like cell lines.Combined staining of CK8/18/19 and CD49f after CD146/EpCAM enrichment is likely to further improve CTC detection in breast cancer.

Additional Metadata
Keywords Breast cancer, CD49f, CellSearch, Circulating tumor cells, Cytokeratin
Persistent URL dx.doi.org/10.1016/j.canlet.2011.12.031, hdl.handle.net/1765/65283
Journal Cancer Letters
Citation
Mostert, B, Kraan, J, Sieuwerts, A.M, van der Spoel, P, Bolt-de Vries, J, Prager-van der Smissen, W.J.C, … Sleijfer, S. (2012). CD49f-based selection of circulating tumor cells (CTCs) improves detection across breast cancer subtypes. Cancer Letters, 319(1), 49–55. doi:10.1016/j.canlet.2011.12.031